批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2021/12/13 |
ORIG-1(原始申请) |
Approval |
|
STANDARD
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 无 |
与本品相关的专利信息(来自FDA橙皮书Orange Book)
| 关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
| 无 |
与本品治疗等效的药品
>>>活性成分:FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE; 剂型/给药途径:POWDER;INHALATION; 规格:0.1MG/INH;EQ 0.05MG BASE/INH; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 021077 |
001 |
NDA |
ADVAIR DISKUS 100/50 |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.1MG/INH;EQ 0.05MG BASE/INH |
Prescription |
Yes |
Yes |
AB |
2000/08/24
|
GLAXO GRP LTD |
| 208891 |
001 |
ANDA |
WIXELA INHUB |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.1MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2019/01/30
|
MYLAN |
| 203433 |
001 |
ANDA |
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.1MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2020/12/17
|
HIKMA |
| 213948 |
001 |
ANDA |
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.1MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2021/12/13
|
TEVA PHARMS USA |
>>>活性成分:FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE; 剂型/给药途径:POWDER;INHALATION; 规格:0.25MG/INH;EQ 0.05MG BASE/INH; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 021077 |
002 |
NDA |
ADVAIR DISKUS 250/50 |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.25MG/INH;EQ 0.05MG BASE/INH |
Prescription |
Yes |
Yes |
AB |
2000/08/24
|
GLAXO GRP LTD |
| 208891 |
002 |
ANDA |
WIXELA INHUB |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.25MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2019/01/30
|
MYLAN |
| 203433 |
002 |
ANDA |
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.25MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2020/12/17
|
HIKMA |
| 213948 |
002 |
ANDA |
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.25MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2021/12/13
|
TEVA PHARMS USA |
>>>活性成分:FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE; 剂型/给药途径:POWDER;INHALATION; 规格:0.5MG/INH;EQ 0.05MG BASE/INH; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 021077 |
003 |
NDA |
ADVAIR DISKUS 500/50 |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.5MG/INH;EQ 0.05MG BASE/INH |
Prescription |
Yes |
Yes |
AB |
2000/08/24
|
GLAXO GRP LTD |
| 208891 |
003 |
ANDA |
WIXELA INHUB |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.5MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2019/01/30
|
MYLAN |
| 213948 |
003 |
ANDA |
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.5MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2021/12/13
|
TEVA PHARMS USA |
| 203433 |
003 |
ANDA |
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE |
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
POWDER;INHALATION |
0.5MG/INH;EQ 0.05MG BASE/INH |
Prescription |
No |
No |
AB |
2023/12/19
|
HIKMA |